Literature DB >> 21575465

[Nedaplatin or cisplatin combined with 5-fluorouracil for treatment of stage III-IVa nasopharyngeal carcinoma: a randomized controlled study].

Ka-Jia Cao1, Ai-Lan Zhang, Wen-Juan Ma, Pei-Yu Huang, Dong-Hua Luo, Wei-Xiong Xia.   

Abstract

OBJECTIVE: To compare the efficacy and side effects of nedaplatin plus 5-fluorouracil (5-Fu) and cisplatin plus 5-Fu for treatment of stage III-IVa nasopharyngeal carcinoma (NPC).
METHODS: A total of 100 patients with NPC proved by histopathology were divided into nedaplatin plus 5-Fu group (NF group) and cisplatin plus 5-Fu group (PF group), 50 cases in each group. NF group: nedaplatin 30 mg/m(2), d1-d3, 5-Fu 500 mg/m(2) d1-d5, repeated every 3 weeks for 2 cycles. PF group: cisplatin 30 mg/m(2) d1-d3, 5-Fu 500 mg/m(2) d1-d5, repeated every 3 weeks for 2 cycles. χ(2) test was used to compare the efficacy and side-effects of the two groups.
RESULTS: All the 100 cases were evaluable and their clinical data in the two groups were comparable. Six patients with complete response were observed, 3 cases in NF group and 3 in PF group. The overall response rates were 86.0% in NF group and 84.0% in PF group, with no significant difference (χ(2) = 0.078, P = 0.779). The rates of leukocytopenia, thrombocytopenia, impairment of hepatic and renal function were similar whereas more patients in the PF group than in the NF group suffered from nausea and vomiting (88.0% vs. 56.0%, P = 0.000).
CONCLUSIONS: Nedaplatin plus 5-Fu is an effective treatment regimen for NPC. When compared with PF regimen, the response rate is similar. However, NF regimen shows a significant superiority in reducing nausea and vomiting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575465

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  4 in total

1.  Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer.

Authors:  Jinlu Shan; Yanli Xiong; Dong Wang; Mingfang Xu; Y I Yang; Kan Gong; Zhenzhou Yang; G E Wang; Xueqin Yang
Journal:  Mol Clin Oncol       Date:  2015-02-06

2.  Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial.

Authors:  Chunyuan Tang; Fang Wu; Rensheng Wang; Heming Lu; Guisheng Li; Meilian Liu; Haisheng Zhu; Jinxian Zhu; Yong Zhang; Kai Hu
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

3.  Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.

Authors:  Zhiru Li; Chao Li; Dong Yang; Junmei Song; Ting Liu; Ziyan Zhou; Lifang Zhou; Min Kang
Journal:  BMC Cancer       Date:  2022-06-06       Impact factor: 4.638

4.  Neoadjuvant Chemotherapy with Fluorouracil plus Nedaplatin or Cisplatin for Locally Advanced Nasopharyngeal Carcinoma: a Retrospective Study.

Authors:  Tongxin Liu; Quanquan Sun; Jing Chen; Bin Li; Weifeng Qin; Fangzheng Wang; Zhimin Ye; Fujun Hu
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.